Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck Is At Support And Should Go Higher (Technical Analysis)
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for continued growth and extended patent protection through a subcutaneous formulation. Strategic acquisitions are broadening Merck's pipeline and should reduce its reliance on Keytruda, despite the short-term profit impacts.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Merck Stock a Buy?
Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
Merck says trial of combination treatment for colon cancer failed to meet main goal
Merck & Co.'s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.
Merck (MRK) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab shows improved efficacy over Merck's Keytruda in Phase III trials, targeting both PD-1 and VEGF, potentially expanding the PD-1 inhibitor market. Despite risks, Summit's promising data and significant insider investment suggest a speculative buy, with potential for major upside if FDA approval is achieved. Ivonescimab's dual mechanism could disrupt the oncology market, similar to Regeneron's Eylea, positioning Summit for substantial growth if it captures market share.
